SLC25A51 and mitochondrial NAD+ transport in acute myeloid leukemia: mechanisms, therapeutic potential, and translational perspectives.
Leukemia cells depend on a specific transport system for survival, offering a potential new angle to fight drug-resistant acute myeloid leukemia.
SLC25A51-mediated mitochondrial NAD+ transport is a novel metabolic vulnerability in AML with therapeutic targeting potential; mitochondrial metabolic rewiring represents an alternative approach to standard cytotoxic therapy resistance. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- narrative_review
- Category
- hematologic_malignancies
- Maturity
- Exploratory
- Journal
- Human Cell
Why it surfaced
Novel metabolic target (SLC25A51/NAD+ transport) in AML with translational perspective; relevant to precision therapeutic development in high-unmet-need disease.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.